dementia and psych meds andrew s. rosenzweig, md, mph medical director, medoptions assistant...
TRANSCRIPT
![Page 1: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/1.jpg)
Dementia and Psych MedsDementia and Psych Meds
Andrew S. Rosenzweig, MD, MPHAndrew S. Rosenzweig, MD, MPH
Medical Director, MedOptionsMedical Director, MedOptions
Assistant Clinical Professor, Brown UniversityAssistant Clinical Professor, Brown University
![Page 2: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/2.jpg)
What Is A Geriatric Psychiatrist?What Is A Geriatric Psychiatrist?
A geriatric psychiatrist is a medical doctor with A geriatric psychiatrist is a medical doctor with special training in the diagnosis and treatment special training in the diagnosis and treatment of mental disorders that may occur in older of mental disorders that may occur in older adults. These disorders include, but are not adults. These disorders include, but are not limited to, dementia, depression, bipolar limited to, dementia, depression, bipolar disorder, anxiety and late-life schizophrenia.disorder, anxiety and late-life schizophrenia.
![Page 3: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/3.jpg)
Demographics of the Elderly PopulationDemographics of the Elderly Population
By 2030, older adults will account for 20% of the By 2030, older adults will account for 20% of the population, up from 13% in 2000population, up from 13% in 2000
At age 85+, there are 241 women for every 100 menAt age 85+, there are 241 women for every 100 men
Mental disorders in older adults are under-reportedMental disorders in older adults are under-reported
The rate of suicide is highest among older adults The rate of suicide is highest among older adults compared to any other age groupcompared to any other age group
![Page 4: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/4.jpg)
Most Common Psychiatric Disorders in Late LifeMost Common Psychiatric Disorders in Late Life
OutpatientOutpatient
DementiaDementia
DepressionDepression
Substance Abuse (alcohol)Substance Abuse (alcohol)
Psychotic DisordersPsychotic Disorders
Long-Term CareLong-Term Care
DementiaDementia
Other Organic Mental DisordersOther Organic Mental Disorders
Mood DisordersMood Disorders
MR-DDMR-DD
Psychotic DisordersPsychotic Disorders
![Page 5: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/5.jpg)
Alzheimer’s Disease (AD): Alzheimer’s Disease (AD): More Than Just Memory LossMore Than Just Memory Loss
AD is a progressive, degenerative disease involving:AD is a progressive, degenerative disease involving:– Loss of memory and other cognitiveLoss of memory and other cognitive
functions functions– Decline in ability to perform activities Decline in ability to perform activities
of daily living of daily living– Changes in personality and behaviorChanges in personality and behavior– Increases in resource utilizationIncreases in resource utilization– Eventual nursing home placementEventual nursing home placement
![Page 6: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/6.jpg)
“A Peculiar Disease of the Cerebral Cortex”
Alzheimer’s Original Case Report (1907)Alzheimer’s Original Case Report (1907)
The first case report of Alzheimer’s disease highlighted The first case report of Alzheimer’s disease highlighted the presence of psychosis and agitation in these the presence of psychosis and agitation in these patientspatients
““The first noticeable symptom of illness was suspiciousness The first noticeable symptom of illness was suspiciousness of her husband…believing that people were out to murder of her husband…believing that people were out to murder her”her”
““She screams that her doctor wants to cut her open; at times, She screams that her doctor wants to cut her open; at times, she seems to have auditory hallucinations”she seems to have auditory hallucinations”
Source: Alzheimer A. Source: Alzheimer A. Allegmeine Zeitschrift für PsychiatrieAllegmeine Zeitschrift für Psychiatrie. 1907;64:146-148.. 1907;64:146-148.
![Page 7: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/7.jpg)
Behavioral and Psychological Behavioral and Psychological Symptoms of DementiaSymptoms of Dementia
PsychosisPsychosis DelusionsDelusions ParanoiaParanoia HallucinationsHallucinations
AgitationAgitation Aggression Aggression CombativenessCombativeness Hyperactivity Hyperactivity
(including (including wandering)wandering)
HypervocalizationHypervocalization DisinhibitionDisinhibition
Source: Finkel et al. Am J Geriatr Psychiatry. 1998;6:97-100.
![Page 8: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/8.jpg)
Behaviors Reported in Agitation and AggressionBehaviors Reported in Agitation and Aggression
AgitationAgitation
PhysicalPhysical: pacing, inappropriate robing/disrobing, trying to get to a different place, handling : pacing, inappropriate robing/disrobing, trying to get to a different place, handling things inappropriately, restlessness, stereotypythings inappropriately, restlessness, stereotypy
VerbalVerbal: Complaining, requests for attention, negativism, : Complaining, requests for attention, negativism, repeated repeated questions/phrases, screamingquestions/phrases, screaming
AggressionAggression
PhysicalPhysical: hitting, kicking, pushing, scratching, tearing, : hitting, kicking, pushing, scratching, tearing, biting, spittingbiting, spitting
VerbalVerbal: threats, accusations, name-calling, obscenities: threats, accusations, name-calling, obscenities
![Page 9: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/9.jpg)
Psychosis and Agitation:What We Know
Common in Alzheimer’s disease and Common in Alzheimer’s disease and other dementing illnessesother dementing illnesses
Major source of caregiver distressMajor source of caregiver distress
Contribute to Contribute to – Premature institutionalizationPremature institutionalization– Increased costIncreased cost
Sources: Drevets et al. Sources: Drevets et al. Biol PsychiatryBiol Psychiatry. 1989;25:39-48./Ellgring. 1989;25:39-48./Ellgring. NeurologyNeurology. 1999:52(suppl 3):S17-S20./Rabins PV. . 1999:52(suppl 3):S17-S20./Rabins PV. Int Int Psychogeriatr. Psychogeriatr. 1991;3:319-324.1991;3:319-324.
![Page 10: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/10.jpg)
Prevalence of Symptoms of Prevalence of Symptoms of Psychosis and Agitation in DementiaPsychosis and Agitation in Dementia
Cache County Study of Memory in Aging (CCSMA)Cache County Study of Memory in Aging (CCSMA)
First US population study of behavioral disturbances in First US population study of behavioral disturbances in dementiadementia
Evaluated the prevalence and severity of mental and behavioral Evaluated the prevalence and severity of mental and behavioral disturbances in the elderlydisturbances in the elderly
5092 individuals were screened5092 individuals were screened
Participants with dementia (n=329) were compared to control Participants with dementia (n=329) were compared to control group without dementia (n=673)group without dementia (n=673)
Source: Lyketsos CG et al. Source: Lyketsos CG et al. Am J PsychiatryAm J Psychiatry. 2000;157:708-714.. 2000;157:708-714.
20
![Page 11: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/11.jpg)
Prevalence of Symptoms of Prevalence of Symptoms of Psychosis and Agitation in DementiaPsychosis and Agitation in Dementia
NPI Item
Dementia(n=329)
%
No Dementia(n=673)
%
Apathy Depression Agitation/aggression Irritability DelusionsAnxietyAberrant motor behaviorHallucinationsDisinhibitionElation
27.423.723.720.418.517.014.313.79.10.9
3.17.02.84.52.45.60.40.60.90.3
Source: Adapted with permission from Lyketsos CG et al. Source: Adapted with permission from Lyketsos CG et al. Am J PsychiatryAm J Psychiatry. 2000;157:708-714. American Psychiatric Association.. 2000;157:708-714. American Psychiatric Association.
21
![Page 12: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/12.jpg)
Sources: Rabins PV. Sources: Rabins PV. Int Psychogeriatr. Int Psychogeriatr. 1991;3:319-324./Stoppe et al. 1991;3:319-324./Stoppe et al. Drugs AgingDrugs Aging. 1999;14:41-54.. 1999;14:41-54.
Causes of Distress to Caregivers
Physical violencePhysical violence Catastrophic Catastrophic
reactionsreactions HittingHitting Making accusationsMaking accusations
SuspiciousnessSuspiciousness IncontinenceIncontinence Memory disturbanceMemory disturbance Inappropriate sexual Inappropriate sexual
behaviorbehavior
Disturbing symptomsDisturbing symptoms
![Page 13: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/13.jpg)
Sources: Deutsch et al. Sources: Deutsch et al. Am J Psychiatry. Am J Psychiatry. 1991;148:1159-1163./Drevets. 1991;148:1159-1163./Drevets. Biol PsychiatryBiol Psychiatry. 1989;25:39-48.. 1989;25:39-48.
Delusions in Alzheimer’s DiseaseDelusions in Alzheimer’s Disease
Delusional thought content (eg, paranoia) is Delusional thought content (eg, paranoia) is common (studies suggest 34% to 50% incidence)common (studies suggest 34% to 50% incidence)
Common delusionsCommon delusions– Marital infidelityMarital infidelity– Patients, staff are Patients, staff are
trying to hurt metrying to hurt me– Staff, family members Staff, family members
are impersonatorsare impersonators– People are stealingPeople are stealing
my thingsmy things
– My house is not my homeMy house is not my home– Strangers living in my homeStrangers living in my home– Misidentification of peopleMisidentification of people– People on TV are realPeople on TV are real
![Page 14: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/14.jpg)
Effect of Losses in Dementia Effect of Losses in Dementia
Normal Feelings Thoughts BehaviorsNormal Feelings Thoughts Behaviors
Dementia Feelings Short Circuit BehaviorsDementia Feelings Short Circuit Behaviors
Thoughts are impaired by Thoughts are impaired by losseslosses of: of:
memorymemory of coping with past situations of coping with past situations
judgmentjudgment to select among alternative actions to select among alternative actions
insightinsight needed to solve problems needed to solve problems
inhibitionsinhibitions and and impulse control impulse control needed to show restraintneeded to show restraint
![Page 15: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/15.jpg)
Practical Recommendations: Decrease EscalationPractical Recommendations: Decrease Escalation
Approach in a calm mannerApproach in a calm manner
Use distraction: food, drink, musicUse distraction: food, drink, music
Maintain eye contact and comfortable postureMaintain eye contact and comfortable posture
Match verbal and non-verbal signalsMatch verbal and non-verbal signals
Identify and state the affect observed in the patientIdentify and state the affect observed in the patient
Identify what is triggering the behaviorIdentify what is triggering the behavior
Modify the environmentModify the environment
![Page 16: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/16.jpg)
Target Symptoms for TreatmentTarget Symptoms for Treatment
Physical aggressionPhysical aggression
AgitationAgitation
Delusions/paranoiaDelusions/paranoia
HallucinationsHallucinations
Sleep/wake cycle Sleep/wake cycle changeschanges
Depression, Depression, withdrawalwithdrawal
Eating problemsEating problems
Verbal outburstsVerbal outbursts
![Page 17: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/17.jpg)
PharmacotherapyPharmacotherapy
AnticonvulsantsAnticonvulsants
AntidepressantsAntidepressants
Beta-blockersBeta-blockers
BenzodiazepinesBenzodiazepines
Medications for treating target symptomsMedications for treating target symptoms Trazodone,Trazodone, buspironebuspirone
Acetylcholinesterase Acetylcholinesterase inhibitorsinhibitors
AntipsychoticsAntipsychotics
MemantineMemantine
![Page 18: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/18.jpg)
AnticonvulsantsAnticonvulsants
Divalproex, carbamazepineDivalproex, carbamazepine
Open trials, case reports, and 4 controlled Open trials, case reports, and 4 controlled studiesstudies
May have specific utility for paroxysmal May have specific utility for paroxysmal and aggressive behavior dyscontrol in the and aggressive behavior dyscontrol in the absence of psychotic symptomsabsence of psychotic symptoms
Sources: Chambers et al.Sources: Chambers et al. IRCS Med Sci IRCS Med Sci. 1982;10:505-506./Lott AD et al. . 1982;10:505-506./Lott AD et al. J Neuropsychiatry Clin NeurosciJ Neuropsychiatry Clin Neurosci. . 1995;7:314-319./Mellow et al. 1995;7:314-319./Mellow et al. J Geriatr Psychiatry NeurolJ Geriatr Psychiatry Neurol. 1993;6:205-209./Tariot PN et al. . 1993;6:205-209./Tariot PN et al. J Am Geriatr SocJ Am Geriatr Soc. . 1994;42:1160-1166./Tariot et al. 1994;42:1160-1166./Tariot et al. Am J Psychiatry.Am J Psychiatry. 1998;155:54-61./ 1998;155:54-61./Tariot et al. J Clin Psychiatry 1999;60:684-9.
![Page 19: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/19.jpg)
Divalproex:Divalproex: Dementia-Related AgitationDementia-Related Agitation
Efficacy data emerging Efficacy data emerging
Gastrointestinal intolerance and Gastrointestinal intolerance and excessive sedation may limit utility*excessive sedation may limit utility*
Hepatotoxicity and thrombocytopenia are Hepatotoxicity and thrombocytopenia are rare but serious potential side effects rare but serious potential side effects
Source: Lott et al. Source: Lott et al. J Neuropsychiatry Clin NeurosciJ Neuropsychiatry Clin Neurosci. 1995;7:314-319./Mellow et al. . 1995;7:314-319./Mellow et al. J Geriatr Psychiatry NeurolJ Geriatr Psychiatry Neurol. . 1993;6:205-209.1993;6:205-209.
*A placebo-controlled trial of divalproex for the treatment of behavioral disturbances in the elderly was recently halted due *A placebo-controlled trial of divalproex for the treatment of behavioral disturbances in the elderly was recently halted due to excessive somnolence and weight loss in the divalproex group (C. Spath, RPh, oral communication, January 2000). to excessive somnolence and weight loss in the divalproex group (C. Spath, RPh, oral communication, January 2000). As a result, a lower dose and more conservative titration schedule will be utilized in future trials.As a result, a lower dose and more conservative titration schedule will be utilized in future trials.
![Page 20: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/20.jpg)
BenzodiazepinesBenzodiazepines
Minimal efficacy dataMinimal efficacy data
SedatingSedating
Cause fallsCause falls
Further inhibit learning and memoryFurther inhibit learning and memory
Paradoxical disinhibitionParadoxical disinhibition
Commonly usedCommonly used– lorazepamlorazepam
– oxazepamoxazepam
Source: Coccaro.Source: Coccaro. Am J Psychiatry Am J Psychiatry. 1990;147:1640-1645.. 1990;147:1640-1645.
![Page 21: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/21.jpg)
Acetylcholinesterase InhibitorsAcetylcholinesterase Inhibitors
Drugs used to treat Alzheimer’s disease act by inhibiting Drugs used to treat Alzheimer’s disease act by inhibiting acetylcholinesterase activityacetylcholinesterase activity
These drugs block the esterase-mediated metabolism of These drugs block the esterase-mediated metabolism of acetylcholine to choline and acetate. This results in:acetylcholine to choline and acetate. This results in:– Increased acetylcholine in the synaptic cleftIncreased acetylcholine in the synaptic cleft– Increased availability of acetylcholine for postsynaptic and Increased availability of acetylcholine for postsynaptic and
presynaptic nicotinic presynaptic nicotinic (and muscarinic) acetylcholine receptors(and muscarinic) acetylcholine receptors
Nordberg A, Svensson A-L. Drug Safety. 1998;19:465-480.
![Page 22: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/22.jpg)
Memantine in ADMemantine in AD
FDA approved for moderate-to-severe ADFDA approved for moderate-to-severe AD
Studies show slowing of cognitive decline, stabilization or Studies show slowing of cognitive decline, stabilization or improvement over baseline for >6 monthsimprovement over baseline for >6 months
Slowing of decline in functional outcomesSlowing of decline in functional outcomes
Some behavioral symptom reduction (especially apathy, Some behavioral symptom reduction (especially apathy, anxious/depressive features)anxious/depressive features)
![Page 23: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/23.jpg)
Antipsychotic Drug PrescriptionsAntipsychotic Drug Prescriptions
Source: IMS Health, NDTI. Plymouth Meeting, Pennsylvania. August 1999. Source: IMS Health, NDTI. Plymouth Meeting, Pennsylvania. August 1999.
24%
Total PrescriptionsTotal Prescriptions United States PopulationUnited States Population
OtherOther
ElderlyElderly13%
AntipsychoticAntipsychoticPrescriptions Prescriptions for the Elderlyfor the Elderly
![Page 24: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/24.jpg)
Conventional AntipsychoticsConventional Antipsychotics
Extensive clinical experienceExtensive clinical experience
Modest efficacyModest efficacy
Side effects can hinder treatmentSide effects can hinder treatment
High risk of tardive dyskinesiaHigh risk of tardive dyskinesia
Commonly used in geriatricsCommonly used in geriatrics– HaloperidolHaloperidol
– ThioridazineThioridazine
Source: Tune et al. In: Davidson M, ed. Source: Tune et al. In: Davidson M, ed. Psychiatric Clinics of North America.Psychiatric Clinics of North America. Philadelphia, Penn: WB Saunders Philadelphia, Penn: WB Saunders Co. 1991:353-373.Co. 1991:353-373.
![Page 25: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/25.jpg)
Conventional Antipsychotics:Conventional Antipsychotics: Side Effects Are PredictableSide Effects Are Predictable
Extrapyramidal symptomsExtrapyramidal symptoms
Anticholinergic effects Anticholinergic effects
Cognitive toxicityCognitive toxicity
SedationSedation
Orthostatic hypotension Orthostatic hypotension
Tardive dyskinesiaTardive dyskinesia
Source: Tune et al. In Davidson M, ed. Source: Tune et al. In Davidson M, ed. Psychiatric Clinics of North America.Psychiatric Clinics of North America. Philadelphia, Penn: WB Saunders Co. 1991:353- Philadelphia, Penn: WB Saunders Co. 1991:353-373.373.
![Page 26: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/26.jpg)
Atypical Antipsychotics Atypical Antipsychotics
ClozapineClozapine
Olanzapine Olanzapine
Quetiapine Quetiapine
RisperidoneRisperidone
ZiprasidoneZiprasidone
Aripiprazole Aripiprazole
![Page 27: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/27.jpg)
•• Most studied antipsychotic in the elderlyMost studied antipsychotic in the elderly
•• 3 pivotal placebo-controlled trials in dementia patients (N = 3 pivotal placebo-controlled trials in dementia patients (N =
1306)1306)
•• Side-effects equivalent to placebo in therapeuticSide-effects equivalent to placebo in therapeutic
dose rangedose range
•• Recommended dosing regimen in dementiaRecommended dosing regimen in dementia
–– Starting dose: 0.25 mg to 0.5 mg hsStarting dose: 0.25 mg to 0.5 mg hs
–– Target dose range: 0.5 mg to 1.5 mg hsTarget dose range: 0.5 mg to 1.5 mg hs
Aronson SM. Mental Disorders in the Elderly: New Therapeutic Aproaches 1998. De Deyn PP et al. Neurology 1999.
Falsetti AE. Am J Health-Syst Pharm 2000. Jeste DV et al. J Clin Psychiatry 1996. Snowdon J et al. Am J Geriatr Psychiatry 2002.
Risperidone In Dementia-Related Risperidone In Dementia-Related Psychosis And AgitationPsychosis And Agitation
![Page 28: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/28.jpg)
Risperidone In DementiaRisperidone In Dementia
625 Patients With Dementia625 Patients With Dementia
•• Prospective, 12-week, multicenter,Prospective, 12-week, multicenter,
placebo-controlledplacebo-controlled
•• Randomized to (12 weeks)Randomized to (12 weeks)
–– Risperidone fixed dose (0.5 mg/d, 1 mg/d, 2 mg/d)Risperidone fixed dose (0.5 mg/d, 1 mg/d, 2 mg/d)
–– PlaceboPlacebo
•• Mean age 83 ± 8y; 68% femaleMean age 83 ± 8y; 68% female
•• Mean MMSE 6.6/30Mean MMSE 6.6/30
Katz IR et al. J Clin Psychiatry 1999.
![Page 29: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/29.jpg)
Risperidone In Dementia: ResultsRisperidone In Dementia: Results
•• 1 mg and 2 mg doses efficacious on outcome measures 1 mg and 2 mg doses efficacious on outcome measures
(BEHAVE-AD, CMAI)(BEHAVE-AD, CMAI)
•• 2 mg dose resulted in higher rate of EPS2 mg dose resulted in higher rate of EPS
•• 1 mg dose side effect rate equivalent to placebo1 mg dose side effect rate equivalent to placebo
Katz IR et al. J Clin Psychiatry 1999.
![Page 30: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/30.jpg)
LATE-LIFE DEPRESSIONLATE-LIFE DEPRESSIONLATE-LIFE DEPRESSIONLATE-LIFE DEPRESSION
Four Hallmarks:Four Hallmarks:
Depressed moodDepressed mood
AnhedoniaAnhedonia
Physical symptomsPhysical symptoms
Psychological symptomsPsychological symptoms
Four Hallmarks:Four Hallmarks:
Depressed moodDepressed mood
AnhedoniaAnhedonia
Physical symptomsPhysical symptoms
Psychological symptomsPsychological symptoms
![Page 31: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/31.jpg)
DEPRESSED MOODDEPRESSED MOODHallmark 1Hallmark 1
DEPRESSED MOODDEPRESSED MOODHallmark 1Hallmark 1
Neither necessary, nor sufficientNeither necessary, nor sufficient
Can be misleadingCan be misleading
Beware of asking the question, “Are Beware of asking the question, “Are you depressed?”you depressed?”
Neither necessary, nor sufficientNeither necessary, nor sufficient
Can be misleadingCan be misleading
Beware of asking the question, “Are Beware of asking the question, “Are you depressed?”you depressed?”
![Page 32: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/32.jpg)
ANHEDONIAANHEDONIA Hallmark 2Hallmark 2
ANHEDONIAANHEDONIA Hallmark 2Hallmark 2
Loss of interest or pleasureLoss of interest or pleasure
May be most important andMay be most important and
useful hallmarkuseful hallmark Ask, “What do you enjoy doing?”Ask, “What do you enjoy doing?”
Loss of interest or pleasureLoss of interest or pleasure
May be most important andMay be most important and
useful hallmarkuseful hallmark Ask, “What do you enjoy doing?”Ask, “What do you enjoy doing?”
![Page 33: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/33.jpg)
PHYSICAL SYMPTOMSPHYSICAL SYMPTOMS Hallmark 3Hallmark 3
PHYSICAL SYMPTOMSPHYSICAL SYMPTOMS Hallmark 3Hallmark 3
Sleep disturbanceSleep disturbance
Appetite or weight changeAppetite or weight change
Low energy or fatigueLow energy or fatigue
Psychomotor changesPsychomotor changes
Sleep disturbanceSleep disturbance
Appetite or weight changeAppetite or weight change
Low energy or fatigueLow energy or fatigue
Psychomotor changesPsychomotor changes
![Page 34: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/34.jpg)
PSYCHOLOGICAL SYMPTOMS PSYCHOLOGICAL SYMPTOMS Hallmark 4Hallmark 4
PSYCHOLOGICAL SYMPTOMS PSYCHOLOGICAL SYMPTOMS Hallmark 4Hallmark 4
Low self-esteem or guiltLow self-esteem or guilt
Poor concentrationPoor concentration
Suicidal ideation or persistentSuicidal ideation or persistent thoughts of deaththoughts of death
Low self-esteem or guiltLow self-esteem or guilt
Poor concentrationPoor concentration
Suicidal ideation or persistentSuicidal ideation or persistent thoughts of deaththoughts of death
![Page 35: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/35.jpg)
MANAGEMENTMANAGEMENTMANAGEMENTMANAGEMENT
Support Support
Psychotherapy Psychotherapy
PsychopharmacologyPsychopharmacology
Electroconvulsive therapyElectroconvulsive therapy
![Page 36: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/36.jpg)
NON-SPECIFIC SUPPORTNON-SPECIFIC SUPPORT
Reflective listeningReflective listening– If I understand you correctly, you…If I understand you correctly, you…
Empathic communicationEmpathic communication– I can see you feel very sad…(reflection)I can see you feel very sad…(reflection)– I can understand…(legitimation)I can understand…(legitimation)
Specific offer of supportSpecific offer of support– I am here to help you…I am here to help you…
PartnershipPartnership– Let’s you and I together…Let’s you and I together…
RespectRespect– I am very impressed by…I am very impressed by…
![Page 37: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/37.jpg)
PSYCHOTHERAPIESPSYCHOTHERAPIES
Cognitive-behavioral therapyCognitive-behavioral therapy– Negative thinking, expectations of self and worldNegative thinking, expectations of self and world
Interpersonal psychotherapyInterpersonal psychotherapy– Role changeRole change
Problem-solving therapy (pleasant activities)Problem-solving therapy (pleasant activities)
Life narrative reviewLife narrative review– Integrity vs. despair Integrity vs. despair
Grief counselingGrief counseling
![Page 38: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/38.jpg)
PSYCHOTHERAPYPSYCHOTHERAPYPSYCHOTHERAPYPSYCHOTHERAPY EffectiveEffective
– Mild to moderate major depressionMild to moderate major depression– Adjunct to antidepressantsAdjunct to antidepressants– Chronic depressionChronic depression
Possibly effectivePossibly effective– Minor depressionMinor depression– For patients in life transitions or with personal For patients in life transitions or with personal
conflictsconflicts– Depression in long-term careDepression in long-term care– Depression in ADDepression in AD
EffectiveEffective– Mild to moderate major depressionMild to moderate major depression– Adjunct to antidepressantsAdjunct to antidepressants– Chronic depressionChronic depression
Possibly effectivePossibly effective– Minor depressionMinor depression– For patients in life transitions or with personal For patients in life transitions or with personal
conflictsconflicts– Depression in long-term careDepression in long-term care– Depression in ADDepression in AD
![Page 39: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/39.jpg)
PHARMACOTHERAPYPHARMACOTHERAPYPHARMACOTHERAPYPHARMACOTHERAPY
Effective Effective – Major depressionMajor depression
– Chronic depression (dysthymia)Chronic depression (dysthymia)
Inconclusive evidence to date Inconclusive evidence to date – Minor depressionMinor depression– Depression of AD (7 RCT)Depression of AD (7 RCT)
Lyketsos, Am J Psych 2000Lyketsos, Am J Psych 2000
Effective Effective – Major depressionMajor depression
– Chronic depression (dysthymia)Chronic depression (dysthymia)
Inconclusive evidence to date Inconclusive evidence to date – Minor depressionMinor depression– Depression of AD (7 RCT)Depression of AD (7 RCT)
Lyketsos, Am J Psych 2000Lyketsos, Am J Psych 2000
![Page 40: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/40.jpg)
TREATMENT GUIDELINESTREATMENT GUIDELINESTREATMENT GUIDELINESTREATMENT GUIDELINES
Titrate agent to achieve Titrate agent to achieve
therapeutic dose or remission therapeutic dose or remission
Full effect may take 4-6 weeksFull effect may take 4-6 weeks
Continue for 4-9 months after full remissionContinue for 4-9 months after full remission
Use maintenance medication for recurrent Use maintenance medication for recurrent depressionsdepressions
Titrate agent to achieve Titrate agent to achieve
therapeutic dose or remission therapeutic dose or remission
Full effect may take 4-6 weeksFull effect may take 4-6 weeks
Continue for 4-9 months after full remissionContinue for 4-9 months after full remission
Use maintenance medication for recurrent Use maintenance medication for recurrent depressionsdepressions
![Page 41: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/41.jpg)
ANTIDEPRESSANTSANTIDEPRESSANTSANTIDEPRESSANTSANTIDEPRESSANTS
TRICYCLICSTRICYCLICS SSRIsSSRIs
citalopram (Celexa)citalopram (Celexa) fluoxetine (Prozac)fluoxetine (Prozac) paroxetine (Paxil)paroxetine (Paxil) sertraline (Zoloft)sertraline (Zoloft)
OTHER NEW AGENTSOTHER NEW AGENTS bupropion (Wellbutrin) - DA/NEbupropion (Wellbutrin) - DA/NE mirtazapine (Remeron) - NE/5HTmirtazapine (Remeron) - NE/5HT nefazodone (Serzone) - SRI/5HTnefazodone (Serzone) - SRI/5HT venlafaxine (Effexor) - SRI/NRIvenlafaxine (Effexor) - SRI/NRI
TRICYCLICSTRICYCLICS SSRIsSSRIs
citalopram (Celexa)citalopram (Celexa) fluoxetine (Prozac)fluoxetine (Prozac) paroxetine (Paxil)paroxetine (Paxil) sertraline (Zoloft)sertraline (Zoloft)
OTHER NEW AGENTSOTHER NEW AGENTS bupropion (Wellbutrin) - DA/NEbupropion (Wellbutrin) - DA/NE mirtazapine (Remeron) - NE/5HTmirtazapine (Remeron) - NE/5HT nefazodone (Serzone) - SRI/5HTnefazodone (Serzone) - SRI/5HT venlafaxine (Effexor) - SRI/NRIvenlafaxine (Effexor) - SRI/NRI
![Page 42: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/42.jpg)
ADVANTAGES OF SSRIs ADVANTAGES OF SSRIs ANDAND OTHER NEW AGENTSOTHER NEW AGENTS
ADVANTAGES OF SSRIs ADVANTAGES OF SSRIs ANDAND OTHER NEW AGENTSOTHER NEW AGENTS
Fewer side effectsFewer side effects Safety profile Safety profile Increased patient satisfaction Increased patient satisfaction Improved adherence to therapyImproved adherence to therapy Cost savingsCost savings
Fewer side effectsFewer side effects Safety profile Safety profile Increased patient satisfaction Increased patient satisfaction Improved adherence to therapyImproved adherence to therapy Cost savingsCost savings
![Page 43: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/43.jpg)
CHOOSING AMONG SSRIs CHOOSING AMONG SSRIs AND AND OTHER NEW AGENTSOTHER NEW AGENTS
CHOOSING AMONG SSRIs CHOOSING AMONG SSRIs AND AND OTHER NEW AGENTSOTHER NEW AGENTS
Evaluate:Evaluate:
half-lifehalf-life
drug interactionsdrug interactions
side effectsside effects
Evaluate:Evaluate:
half-lifehalf-life
drug interactionsdrug interactions
side effectsside effects
![Page 44: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/44.jpg)
HALF-LIFEHALF-LIFEHALF-LIFEHALF-LIFE
LongLong (longer than 1 day) (longer than 1 day) fluoxetine (Prozac)fluoxetine (Prozac)
ShortShort other SSRIs (once a day)other SSRIs (once a day) Effexor XR (once a day)Effexor XR (once a day) Wellbutrin SR (1-2x/day)Wellbutrin SR (1-2x/day) other new agents (2x/day)other new agents (2x/day)
LongLong (longer than 1 day) (longer than 1 day) fluoxetine (Prozac)fluoxetine (Prozac)
ShortShort other SSRIs (once a day)other SSRIs (once a day) Effexor XR (once a day)Effexor XR (once a day) Wellbutrin SR (1-2x/day)Wellbutrin SR (1-2x/day) other new agents (2x/day)other new agents (2x/day)
![Page 45: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/45.jpg)
DRUG INTERACTIONSDRUG INTERACTIONSDRUG INTERACTIONSDRUG INTERACTIONS
Obtain medication historyObtain medication history
Be aware that all drugs canBe aware that all drugs can
affect the action and serumaffect the action and serum
levels of other drugs levels of other drugs
Monitor the clinical effects andMonitor the clinical effects and
serum levels of all medicationsserum levels of all medications
Obtain medication historyObtain medication history
Be aware that all drugs canBe aware that all drugs can
affect the action and serumaffect the action and serum
levels of other drugs levels of other drugs
Monitor the clinical effects andMonitor the clinical effects and
serum levels of all medicationsserum levels of all medications
![Page 46: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/46.jpg)
SIDE EFFECTS SIDE EFFECTS (SSRIs)(SSRIs)
SIDE EFFECTS SIDE EFFECTS (SSRIs)(SSRIs)
Agitation/insomniaAgitation/insomnia
GI distressGI distress
Sexual dysfunctionSexual dysfunction
Agitation/insomniaAgitation/insomnia
GI distressGI distress
Sexual dysfunctionSexual dysfunction
![Page 47: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/47.jpg)
MANAGING SIDE EFFECTSMANAGING SIDE EFFECTSMANAGING SIDE EFFECTSMANAGING SIDE EFFECTS
SedationSedation– Give medication HSGive medication HS
GI distressGI distress– Give medication after mealsGive medication after meals
Anticholinergic effectsAnticholinergic effects– Bulk in diet, lemon dropsBulk in diet, lemon drops
Postural hypotensionPostural hypotension– Hydration, change position slowly, Hydration, change position slowly,
support hosesupport hose
![Page 48: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/48.jpg)
2.2
8.4
16.1
21.1 21.0
15.8
11.19.6
8.5 8.16.0
3.7
1.2 1.6
0.0
5.0
10.0
15.0
20.0
25.0
Illicit Drug or AlcoholIllicit Drug or AlcoholDependence or Abuse, by Age: 2003Dependence or Abuse, by Age: 2003
Percent Dependent or Abusing in Past Year
Age in Years
12-13 14-15 16-17 18-20 21-25 26-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+
Age 50+
![Page 49: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/49.jpg)
4228
5872
90
100.0
20.0
40.0
60.0
80.0
100.0
Alcohol and Illicit Drug Dependence or Alcohol and Illicit Drug Dependence or Abuse, as a Percentage of Total Substance Abuse, as a Percentage of Total Substance
Dependence or Abuse, by Age: 2003Dependence or Abuse, by Age: 2003
Age12 to 25
Age26 to 49
Age 50+
Percent of Substance Dependence/Abuse
Alcohol Only
Illicit Drug
![Page 50: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/50.jpg)
Alcohol and Drug Treatment Admissions: Alcohol and Drug Treatment Admissions: Age 50+, 1992-2002Age 50+, 1992-2002
75 75 71 68 68 69 73 74 76 7580
20 2328 29 31
3642
4957
63
74
0102030405060708090
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Admissions in Thousands
Alcohol Only
Drugs
![Page 51: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/51.jpg)
Key Themes in Late-Life Alcohol Key Themes in Late-Life Alcohol AddictionAddiction
Significant underdiagnosisSignificant underdiagnosis
Ageism, shame, misperceptionsAgeism, shame, misperceptions
Increased vulnerability to negative effects of ETOHIncreased vulnerability to negative effects of ETOH
Increased sensitivity and toleranceIncreased sensitivity and tolerance
![Page 52: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/52.jpg)
ComorbiditiesComorbidities
Increased risk of hypertension, arrhythmia, mi, cardiomyopathyIncreased risk of hypertension, arrhythmia, mi, cardiomyopathy
Hemorrhagic StrokeHemorrhagic Stroke
CirrhosisCirrhosis
GI bleedingGI bleeding
Decreased bone densityDecreased bone density
MalnutritionMalnutrition
Depression, anxietyDepression, anxiety
![Page 53: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/53.jpg)
Risk FactorsRisk Factors
GenderGender
Marital StatusMarital Status
Bereavement and other lossesBereavement and other losses
Lessening of Role ResponsibilitiesLessening of Role Responsibilities
Family historyFamily history
Health care settingsHealth care settings
DepressionDepression
![Page 54: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/54.jpg)
Adverse Effects of Late-life DrinkingAdverse Effects of Late-life Drinking
Decreased quality of lifeDecreased quality of life
Family burdenFamily burden
Medication interactionsMedication interactions
TraumaTrauma
Increased suicide risk (10.6 fold increase with 1-2 Increased suicide risk (10.6 fold increase with 1-2 drinks/day)drinks/day)
Adverse medical outcomesAdverse medical outcomes
![Page 55: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/55.jpg)
Effective Treatment StrategiesEffective Treatment Strategies
Prevention/educationPrevention/education
Brief adviceBrief advice
Brief interventionsBrief interventions
Referral managementReferral management
Specialized treatmentsSpecialized treatments
![Page 56: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/56.jpg)
Examples of treatmentsExamples of treatments
Telephone disease management (TDM)Telephone disease management (TDM)
Cognitive Behavioral Therapy (CBT)Cognitive Behavioral Therapy (CBT)
Twelve step programsTwelve step programs
Motivational interviewingMotivational interviewing
Family involvement/social supportFamily involvement/social support
![Page 57: Dementia and Psych Meds Andrew S. Rosenzweig, MD, MPH Medical Director, MedOptions Assistant Clinical Professor, Brown University](https://reader033.vdocuments.mx/reader033/viewer/2022061305/551430e05503466d1a8b5000/html5/thumbnails/57.jpg)
Examples of treatments (cont)Examples of treatments (cont)
Specialty addiction servicesSpecialty addiction services
Pharmacotherapy:Pharmacotherapy: NaltrexoneNaltrexone AcamprosateAcamprosate AntabuseAntabuse Others (SSRI’s, topiramate, ondansetron)Others (SSRI’s, topiramate, ondansetron)